An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.

DOI: http://doi.org/10.1038/s41598-018-31659-0 Journal: Sci Rep E-pub date: 10 Sep 2018 Authors: G Collord, P Tarpey, N Kurbatova, I Martincorena, S Moran, M Castro, T Nagy, G Bignell, F Maura, MD Young, J Berna, JMC Tubio, CE McMurran, AMH Young, M Sanders, I Noorani, SJ Price, C Watts, E Leipnitz, M Kirsch, G Schackert, D Pearson, A Devadass, Z Ram, VP Collins, K Allinson, MD Jenkinson, R Zakaria, K Syed, CO Hanemann, J Dunn, MW McDermott, RW Kirollos, GS Vassiliou, M Esteller, S Behjati, A Brazma, T Santarius, U McDermott

An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.

Abstract:

Anaplastic meningioma is a rare and aggressive brain tumor characterised by intractable recurrences and dismal outcomes. Here, we present an integrated analysis of the whole genome, transcriptome and methylation profiles of primary and recurrent anaplastic meningioma. A key finding was the delineation of distinct molecular subgroups that were associated with diametrically opposed survival outcomes. Relative to lower grade meningiomas, anaplastic tumors harbored frequent driver mutations in SWI/SNF complex genes, which were confined to the poor prognosis subgroup. Aggressive disease was further characterised by transcriptional evidence of increased PRC2 activity, stemness and epithelial-to-mesenchymal transition. Our analyses discern biologically distinct variants of anaplastic meningioma with prognostic and therapeutic significance.